Interstitial Lung Disease (ILD) Market - Global Outlook and Forecast 2021-2027

April 2021 | 93 pages | ID: IF513E40EF04EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Interstitial Lung Disease (ILD) in Global, including the following market information:

Global Interstitial Lung Disease (ILD) Market Revenue, 2016-2021, 2022-2027, ($ millions)

Global top five companies in 2020 (%)

The global Interstitial Lung Disease (ILD) market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Interstitial Lung Disease (ILD) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Interstitial Lung Disease (ILD) Market, By Type, 2016-2021, 2022-2027 ($ millions)

Global Interstitial Lung Disease (ILD) Market Segment Percentages, By Type, 2020 (%)

• Interstitial Pneumonia
• Idiopathic Pulmonary Fibrosis
• Nonspecific Interstitial Pneumonitis
• Hypersensitivity Pneumonitis
• Cryptogenic Organizing Pneumonia
• Acute Interstitial Pneumonitis
• Desquamative Interstitial Pneumonitis
• Others

China Interstitial Lung Disease (ILD) Market, By Application, 2016-2021, 2022-2027 ($ millions)

China Interstitial Lung Disease (ILD) Market Segment Percentages, By Application, 2020 (%)

• Adults
• Children

Global Interstitial Lung Disease (ILD) Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)

Global Interstitial Lung Disease (ILD) Market Segment Percentages, By Region and Country, 2020 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Total Interstitial Lung Disease (ILD) Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)

Total Interstitial Lung Disease (ILD) Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:

• Boehringer Ingelheim
• Bellerophon Therapeutics, Inc
• Bayer
• Fujirebio (Miraca)
• Philips
• Merck
• Siemens Healthineers

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Interstitial Pneumonia Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Interstitial Pneumonia Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL INTERSTITIAL PNEUMONIA OVERALL MARKET SIZE

2.1 Global Interstitial Pneumonia Market Size: 2021 VS 2027
2.2 Global Interstitial Pneumonia Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Interstitial Pneumonia Players in Global Market
3.2 Top Global Interstitial Pneumonia Companies Ranked by Revenue
3.3 Global Interstitial Pneumonia Revenue by Companies
3.4 Top 3 and Top 5 Interstitial Pneumonia Companies in Global Market, by Revenue in 2020
3.5 Global Companies Interstitial Pneumonia Product Type
3.6 Tier 1, Tier 2 and Tier 3 Interstitial Pneumonia Players in Global Market
  3.6.1 List of Global Tier 1 Interstitial Pneumonia Companies
  3.6.2 List of Global Tier 2 and Tier 3 Interstitial Pneumonia Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - Global Interstitial Pneumonia Market Size Markets, 2021 & 2027
  4.1.2 Usual Interstitial Pneumonitis
  4.1.3 Nonspecific Interstitial Pneumonitis
  4.1.4 Desquamative Interstitial Pneumonitis
  4.1.5 Others
4.2 By Type - Global Interstitial Pneumonia Revenue & Forecasts
  4.2.1 By Type - Global Interstitial Pneumonia Revenue, 2016-2021
  4.2.2 By Type - Global Interstitial Pneumonia Revenue, 2022-2027
  4.2.3 By Type - Global Interstitial Pneumonia Revenue Market Share, 2016-2027

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Interstitial Pneumonia Market Size, 2021 & 2027
  5.1.2 Adults
  5.1.3 Children
5.2 By Application - Global Interstitial Pneumonia Revenue & Forecasts
  5.2.1 By Application - Global Interstitial Pneumonia Revenue, 2016-2021
  5.2.2 By Application - Global Interstitial Pneumonia Revenue, 2022-2027
  5.2.3 By Application - Global Interstitial Pneumonia Revenue Market Share, 2016-2027

6 SIGHTS BY REGION

6.1 By Region - Global Interstitial Pneumonia Market Size, 2021 & 2027
6.2 By Region - Global Interstitial Pneumonia Revenue & Forecasts
  6.2.1 By Region - Global Interstitial Pneumonia Revenue, 2016-2021
  6.2.2 By Region - Global Interstitial Pneumonia Revenue, 2022-2027
  6.2.3 By Region - Global Interstitial Pneumonia Revenue Market Share, 2016-2027
6.3 North America
  6.3.1 By Country - North America Interstitial Pneumonia Revenue, 2016-2027
  6.3.2 US Interstitial Pneumonia Market Size, 2016-2027
  6.3.3 Canada Interstitial Pneumonia Market Size, 2016-2027
  6.3.4 Mexico Interstitial Pneumonia Market Size, 2016-2027
6.4 Europe
  6.4.1 By Country - Europe Interstitial Pneumonia Revenue, 2016-2027
  6.4.2 Germany Interstitial Pneumonia Market Size, 2016-2027
  6.4.3 France Interstitial Pneumonia Market Size, 2016-2027
  6.4.4 U.K. Interstitial Pneumonia Market Size, 2016-2027
  6.4.5 Italy Interstitial Pneumonia Market Size, 2016-2027
  6.4.6 Russia Interstitial Pneumonia Market Size, 2016-2027
  6.4.7 Nordic Countries Interstitial Pneumonia Market Size, 2016-2027
  6.4.8 Benelux Interstitial Pneumonia Market Size, 2016-2027
6.5 Asia
  6.5.1 By Region - Asia Interstitial Pneumonia Revenue, 2016-2027
  6.5.2 China Interstitial Pneumonia Market Size, 2016-2027
  6.5.3 Japan Interstitial Pneumonia Market Size, 2016-2027
  6.5.4 South Korea Interstitial Pneumonia Market Size, 2016-2027
  6.5.5 Southeast Asia Interstitial Pneumonia Market Size, 2016-2027
  6.5.6 India Interstitial Pneumonia Market Size, 2016-2027
6.6 South America
  6.6.1 By Country - South America Interstitial Pneumonia Revenue, 2016-2027
  6.6.2 Brazil Interstitial Pneumonia Market Size, 2016-2027
  6.6.3 Argentina Interstitial Pneumonia Market Size, 2016-2027
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Interstitial Pneumonia Revenue, 2016-2027
  6.7.2 Turkey Interstitial Pneumonia Market Size, 2016-2027
  6.7.3 Israel Interstitial Pneumonia Market Size, 2016-2027
  6.7.4 Saudi Arabia Interstitial Pneumonia Market Size, 2016-2027
  6.7.5 UAE Interstitial Pneumonia Market Size, 2016-2027

7 PLAYERS PROFILES

7.1 Boehringer Ingelheim
  7.1.1 Boehringer Ingelheim Corporate Summary
  7.1.2 Boehringer Ingelheim Business Overview
  7.1.3 Boehringer Ingelheim Interstitial Pneumonia Major Product Offerings
  7.1.4 Boehringer Ingelheim Interstitial Pneumonia Revenue in Global (2016-2021)
  7.1.5 Boehringer Ingelheim Key News
7.2 Bellerophon Therapeutics, Inc
  7.2.1 Bellerophon Therapeutics, Inc Corporate Summary
  7.2.2 Bellerophon Therapeutics, Inc Business Overview
  7.2.3 Bellerophon Therapeutics, Inc Interstitial Pneumonia Major Product Offerings
  7.2.4 Bellerophon Therapeutics, Inc Interstitial Pneumonia Revenue in Global (2016-2021)
  7.2.5 Bellerophon Therapeutics, Inc Key News
7.3 Bayer
  7.3.1 Bayer Corporate Summary
  7.3.2 Bayer Business Overview
  7.3.3 Bayer Interstitial Pneumonia Major Product Offerings
  7.3.4 Bayer Interstitial Pneumonia Revenue in Global (2016-2021)
  7.3.5 Bayer Key News
7.4 Fujirebio (Miraca)
  7.4.1 Fujirebio (Miraca) Corporate Summary
  7.4.2 Fujirebio (Miraca) Business Overview
  7.4.3 Fujirebio (Miraca) Interstitial Pneumonia Major Product Offerings
  7.4.4 Fujirebio (Miraca) Interstitial Pneumonia Revenue in Global (2016-2021)
  7.4.5 Fujirebio (Miraca) Key News
7.5 Philips
  7.5.1 Philips Corporate Summary
  7.5.2 Philips Business Overview
  7.5.3 Philips Interstitial Pneumonia Major Product Offerings
  7.5.4 Philips Interstitial Pneumonia Revenue in Global (2016-2021)
  7.5.5 Philips Key News
7.6 Merck
  7.6.1 Merck Corporate Summary
  7.6.2 Merck Business Overview
  7.6.3 Merck Interstitial Pneumonia Major Product Offerings
  7.6.4 Merck Interstitial Pneumonia Revenue in Global (2016-2021)
  7.6.5 Merck Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Interstitial Lung Disease (ILD) Market Opportunities & Trends in Global Market
Table 2. Interstitial Lung Disease (ILD) Market Drivers in Global Market
Table 3. Interstitial Lung Disease (ILD) Market Restraints in Global Market
Table 4. Key Players of Interstitial Lung Disease (ILD) in Global Market
Table 5. Top Interstitial Lung Disease (ILD) Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Interstitial Lung Disease (ILD) Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Interstitial Lung Disease (ILD) Revenue Share by Companies, 2016-2021
Table 8. Global Companies Interstitial Lung Disease (ILD) Product Type
Table 9. List of Global Tier 1 Interstitial Lung Disease (ILD) Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Interstitial Lung Disease (ILD) Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type – Global Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - Interstitial Lung Disease (ILD) Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - Interstitial Lung Disease (ILD) Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application – Global Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - Interstitial Lung Disease (ILD) Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - Interstitial Lung Disease (ILD) Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region – Global Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global Interstitial Lung Disease (ILD) Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global Interstitial Lung Disease (ILD) Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2022-2027
Table 30. Boehringer Ingelheim Corporate Summary
Table 31. Boehringer Ingelheim Interstitial Lung Disease (ILD) Product Offerings
Table 32. Boehringer Ingelheim Interstitial Lung Disease (ILD) Revenue (US$, Mn), (2016-2021)
Table 33. Bellerophon Therapeutics, Inc Corporate Summary
Table 34. Bellerophon Therapeutics, Inc Interstitial Lung Disease (ILD) Product Offerings
Table 35. Bellerophon Therapeutics, Inc Interstitial Lung Disease (ILD) Revenue (US$, Mn), (2016-2021)
Table 36. Bayer Corporate Summary
Table 37. Bayer Interstitial Lung Disease (ILD) Product Offerings
Table 38. Bayer Interstitial Lung Disease (ILD) Revenue (US$, Mn), (2016-2021)
Table 39. Fujirebio (Miraca) Corporate Summary
Table 40. Fujirebio (Miraca) Interstitial Lung Disease (ILD) Product Offerings
Table 41. Fujirebio (Miraca) Interstitial Lung Disease (ILD) Revenue (US$, Mn), (2016-2021)
Table 42. Philips Corporate Summary
Table 43. Philips Interstitial Lung Disease (ILD) Product Offerings
Table 44. Philips Interstitial Lung Disease (ILD) Revenue (US$, Mn), (2016-2021)
Table 45. Merck Corporate Summary
Table 46. Merck Interstitial Lung Disease (ILD) Product Offerings
Table 47. Merck Interstitial Lung Disease (ILD) Revenue (US$, Mn), (2016-2021)
Table 48. Siemens Healthineers Corporate Summary
Table 49. Siemens Healthineers Interstitial Lung Disease (ILD) Product Offerings
Table 50. Siemens Healthineers Interstitial Lung Disease (ILD) Revenue (US$, Mn), (2016-2021)

List Of Figures

LIST OF FIGURES

Figure 1. Interstitial Lung Disease (ILD) Segment by Type
Figure 2. Interstitial Lung Disease (ILD) Segment by Application
Figure 3. Global Interstitial Lung Disease (ILD) Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Interstitial Lung Disease (ILD) Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global Interstitial Lung Disease (ILD) Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Interstitial Lung Disease (ILD) Revenue in 2020
Figure 8. By Type - Global Interstitial Lung Disease (ILD) Revenue Market Share, 2016-2027
Figure 9. By Application - Global Interstitial Lung Disease (ILD) Revenue Market Share, 2016-2027
Figure 10. By Region - Global Interstitial Lung Disease (ILD) Revenue Market Share, 2016-2027
Figure 11. By Country - North America Interstitial Lung Disease (ILD) Revenue Market Share, 2016-2027
Figure 12. US Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 13. Canada Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe Interstitial Lung Disease (ILD) Revenue Market Share, 2016-2027
Figure 16. Germany Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 17. France Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 19. Italy Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 20. Russia Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia Interstitial Lung Disease (ILD) Revenue Market Share, 2016-2027
Figure 24. China Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 25. Japan Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 28. India Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America Interstitial Lung Disease (ILD) Revenue Market Share, 2016-2027
Figure 30. Brazil Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa Interstitial Lung Disease (ILD) Revenue Market Share, 2016-2027
Figure 33. Turkey Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 34. Israel Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 36. UAE Interstitial Lung Disease (ILD) Revenue, (US$, Mn), 2016-2027
Figure 37. Boehringer Ingelheim Interstitial Lung Disease (ILD) Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Bellerophon Therapeutics, Inc Interstitial Lung Disease (ILD) Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. Bayer Interstitial Lung Disease (ILD) Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. Fujirebio (Miraca) Interstitial Lung Disease (ILD) Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. Philips Interstitial Lung Disease (ILD) Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. Merck Interstitial Lung Disease (ILD) Revenue Year Over Year Growth (US$, Mn) & (2016-2021)